TOP TEN perturbations for 1553281_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1553281_at
Selected probe(set): 235230_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1553281_at (235230_at) across 6673 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-4.704299Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
TGF-ß study 5 (late) / untreated A549 cell sample
Relative Expression (log2-ratio):4.0066195Number of Samples:3 / 3
Experimental | TGF-ß study 5 (late) |
Human A549 cells were treated with 5ng/ml porcine TGF-ß after serum-starving for 24h. Samples were taken 72 hours after TGF-ß treatment. | |
Control | untreated A549 cell sample |
A549 cells were grown for 24 hours. Samples were taken immediately before TGF-ß treatment. |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):3.7866888Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/pH1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.6996813Number of Samples:13 / 2
Experimental | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
influenza virus study 4 (A/H1N1) / mock infected A549 cell sample
Relative Expression (log2-ratio):-3.6883488Number of Samples:3 / 6
Experimental | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. | |
Control | mock infected A549 cell sample |
Human A549 carcinoma cells mock infected (A/H1N1). Sample was taken at 0 hours post-infection. |
keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2
Relative Expression (log2-ratio):-3.654893Number of Samples:2 / 2
Experimental | keratinocyte differentiation study 2 (KLF4 siRNA) |
KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency. | |
Control | keratinocyte differentiation study 2 |
Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency. |
ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.5914783Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
mitomycin study 3 (HPV8 E6; 18h; 2ug/ml) / vehicle (water) treated N/Tert-8E6 cell sample
Relative Expression (log2-ratio):3.4433556Number of Samples:3 / 3
Experimental | mitomycin study 3 (HPV8 E6; 18h; 2ug/ml) |
N/Tert-8E6 human immortalized keratinocytes treated with mitomycin C (2ug/ml) for 18h. Mitomycin C was used for the induction of DNA damage. ATC code: | |
Control | vehicle (water) treated N/Tert-8E6 cell sample |
Human immortalized keratinocyte cell line N/Tert-8E6 treated with water for 18 hours. The cells were grown to approximately 30% confluence in keratinocyte serum-free medium (K-SFM), following which they were harvested by trypsinization and freezing at -80ºC. |
Parkinson's disease study 6 / normal pars reticulata tissue
Relative Expression (log2-ratio):-3.3939028Number of Samples:3 / 4
Experimental | Parkinson's disease study 6 |
Pars reticulata tissue from patients with Parkinson's disease. | |
Control | normal pars reticulata tissue |
Normal pars reticulata tissue. |
CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; glioblastoma, NOS; primary)
Relative Expression (log2-ratio):3.3215475Number of Samples:2 / 3
Experimental | CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted). | |
Control | CNS cancer study 1 (PDX; glioblastoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioblastoma, NOS of the central nervous system (subcutaneously implanted). |